Generali Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.14M Sell
6,779
-906
-12% -$685K 0.09% 190
2026
Q2
$4.79M Buy
7,685
+181
+2% +$123K 0.09% 204
2026
Q1
$5.8M Sell
7,504
-162
-2% -$124K 0.12% 167
2025
Q4
$5.92M Sell
7,666
-4,354
-36% -$2.96M 0.12% 159
2025
Q3
$6.76M Sell
12,020
-664
-5% -$375K 0.14% 133
2025
Q2
$6.66M Buy
12,684
+1,650
+15% +$921K 0.15% 144
2025
Q1
$7M Sell
11,034
-324
-3% -$223K 0.17% 123
2024
Q4
$8.09M Hold
11,358
– – 0.21% 109

Other funds holding REGN

Generali Asset Management's REGN Position: Q3 2026 in Review

Generali Asset Management reduced its Regeneron Pharmaceuticals (REGN) stake by 12% in Q3 2026, selling an estimated $685K and leaving 6,779 shares worth $5.14M. The position accounts for 0.09% of the portfolio, ranked #190.

Generali Asset Management first reported a position in REGN in Q4 2024 and has held it in 8 quarters since. The position peaked at $8.09M in Q4 2024. 1,432 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • Generali Asset Management held 6,779 shares of Regeneron Pharmaceuticals worth $5.14M as of Q3 2026.
  • Generali Asset Management sold 906 Regeneron Pharmaceuticals shares in Q3 2026, an estimated $685K.
  • Regeneron Pharmaceuticals made up 0.09% of Generali Asset Management's portfolio in Q3 2026, its #190 holding.
  • Generali Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 8 quarters since.
  • Generali Asset Management's Regeneron Pharmaceuticals position peaked at $8.09M in Q4 2024.
  • 1,432 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Generali Asset Management's 13F filing for Q3 2026, filed 26 Oct 2026.